Profound Medical Corp. - common stock (PROF)

Profound Medical (NASDAQ:PROF) reported an 86% increase in third-quarter revenue and raised its full-year revenue outlook, as sales of its TULSA-PRO equipment helped drive growth ahead of a planned leadership transition. The company recorded revenue of $9.8 million for the three months ended Septem

Revenue surged on system placements while a leadership transition reshapes the company's top job.

Record orders and expanding payer coverage mark commercial inflection.

Profound Medical (NASDAQ:PROF) reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June. Corporate Controller Matthew Sobczyk

Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base. For the three months ende

PROF stock results show that Profound Medical beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

PROF stock results show that Profound Medical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

PROF stock results show that Profound Medical missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

With U.S. stock futures trading slightly higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.